Astrana Health, Inc. announced its consolidated financial results for the first quarter ended March 31, 2025. The company reported total revenue of $620.39 million, a 53% increase compared to $404.356 million in Q1 2024. Despite the strong top-line growth, net income attributable to Astrana Health, Inc. decreased to $6.692 million from $14.835 million in the prior year's first quarter.
Adjusted EBITDA for Q1 2025 was $36.4 million, down from $42.2 million in Q1 2024. President and CEO Brandon Sim noted that the strong start to the year reflects momentum in building a patient-centered healthcare platform, driven by differentiated clinical capabilities and a technology-enabled delegated model.
The company reiterated its full-year 2025 guidance, expecting total revenue between $2.5 billion and $2.7 billion and Adjusted EBITDA between $170 million and $190 million. This guidance incorporates approximately $15 million in costs for strategic investments and integration efforts, but does not include contributions from acquisitions that have not yet closed.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.